30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Cerevel Therapeutics Holdings Inc (CERE)

Track

Stock chart
Ticker: CERE Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
COLES N ANTHONY
1 sale — total 1,029,535 USD
Planned sale 1 Jul 2024
Value US$644,443.92 | Price 98.36 | Shares 21,103
Proposed sale 1 Jul 2024
Value US$1,307,995.72 | Price 200.59 | Shares 12,473
Planned sale 3 Jun 2024
Value US$2,030,520.00 | Price 40.61 | Shares 50,000
Proposed sale 3 Jun 2024
Value US$2,037,000.00 | Price 40.74 | Shares 50,000
Planned sale 10 May 2024
Value US$2,105,125.00 | Price 42.10 | Shares 50,000
Proposed sale 10 May 2024
Value US$2,115,000.00 | Price 42.30 | Shares 50,000
Planned sale 1 Apr 2024
Value US$2,116,640.00 | Price 42.33 | Shares 50,000
Proposed sale 1 Apr 2024
Value US$2,113,500.00 | Price 42.27 | Shares 50,000
Planned sale 4 Mar 2024
Value US$2,050,550.00 | Price 41.01 | Shares 50,000
Proposed sale 4 Mar 2024
Value US$2,052,500.00 | Price 41.05 | Shares 50,000
Planned sale 29 Feb 2024
Value US$2,057,890.00 | Price 41.16 | Shares 50,000
Proposed sale 29 Feb 2024
Value US$2,061,000.00 | Price 41.22 | Shares 50,000
Sale 7 Feb 2024
Value US$104,109.51 | Price 41.54 | Shares 2,506
Sale 7 Feb 2024
Value US$89,776.80 | Price 41.54 | Shares 2,161
Planned sale 2 Jan 2024
Value US$2,111,815.00 | Price 42.24 | Shares 50,000
Proposed sale 2 Jan 2024
Value US$2,120,000.00 | Price 42.40 | Shares 50,000
Planned sale 26 Dec 2023
Value US$424,700.00 | Price 42.47 | Shares 10,000
Proposed sale 26 Dec 2023
Value US$424,700.00 | Price 42.47 | Shares 10,000
Sale 22 Dec 2023
Value US$331,608.00 | Price 41.45 | Shares 8,000
Proposed sale 22 Dec 2023
Value US$331,608.32 | Price 41.45 | Shares 8,000
Sale 20 Dec 2023
Value US$292,944.87 | Price 41.42 | Shares 7,072
Sale 20 Dec 2023
Value US$326,787.62 | Price 41.42 | Shares 7,889
Sale 20 Dec 2023
Value US$260,469.08 | Price 41.42 | Shares 6,288
Sale 20 Dec 2023
Value US$571,971.55 | Price 41.42 | Shares 13,808
Sale 20 Dec 2023
Value US$420,528.33 | Price 41.42 | Shares 10,152
Sale 20 Dec 2023
Value US$259,143.54 | Price 41.42 | Shares 6,256
Sale 15 Dec 2023
Value US$310,392.75 | Price 41.39 | Shares 7,500
Proposed sale 15 Dec 2023
Value US$310,392.50 | Price 41.39 | Shares 7,500
Planned sale 7 Dec 2023
Value US$413,700.00 | Price 41.37 | Shares 10,000
Proposed sale 7 Dec 2023
Value US$413,700.00 | Price 41.37 | Shares 10,000
Proposed sale 7 Dec 2023
Value US$413,700.00 | Price 41.37 | Shares 10,000
Planned sale 7 Dec 2023
Value US$413,700.00 | Price 41.37 | Shares 10,000
Planned sale 5 Dec 2023
Value US$262,500.00 | Price 35.00 | Shares 7,500
Proposed sale 5 Dec 2023
Value US$262,500.00 | Price 35.00 | Shares 7,500
Planned sale 14 Nov 2023
Value US$573,455.28 | Price 25.13 | Shares 22,824
Planned sale 8 Nov 2023
Value US$2,516.00 | Price 25.16 | Shares 100
Planned sale 7 Nov 2023
Value US$677,555.24 | Price 25.02 | Shares 27,076
Proposed sale 7 Nov 2023
Value US$1,248,000.00 | Price 24.96 | Shares 50,000
Planned sale 3 Nov 2023
Value US$1,561,458.13 | Price 25.43 | Shares 61,401
Proposed sale 3 Nov 2023
Value US$1,244,000.00 | Price 24.88 | Shares 50,000
Planned sale 2 Nov 2023
Value US$972,239.33 | Price 25.19 | Shares 38,599
Proposed sale 2 Nov 2023
Value US$1,267,500.00 | Price 25.35 | Shares 50,000
Planned sale 1 Nov 2023
Value US$753,250.00 | Price 25.00 | Shares 30,130
Proposed sale 1 Nov 2023
Value US$753,250.00 | Price 25.00 | Shares 30,130
Buy 16 Oct 2023
Value US$124,999,986.12 | Price 22.81 | Shares 5,480,052
Buy 16 Oct 2023
Value US$124,999,986.12 | Price 22.81 | Shares 5,480,052
Buy 16 Oct 2023
Value US$124,999,986.12 | Price 22.81 | Shares 5,480,052
Buy 16 Oct 2023
Value US$19,999,990.48 | Price 22.81 | Shares 876,808
Planned sale 7 Sep 2023
Value US$1,203,415.00 | Price 24.07 | Shares 50,000
Proposed sale 7 Sep 2023
Value US$1,213,000.00 | Price 24.26 | Shares 50,000
Buy 4 Aug 2023
Value US$501,793.73 | Price 22.93 | Shares 21,880
Buy 3 Aug 2023
Value US$2,008,811.21 | Price 23.96 | Shares 83,857
Planned sale 11 Jul 2023
Value US$1,501,340.00 | Price 30.03 | Shares 50,000
Proposed sale 11 Jul 2023
Value US$1,529,500.00 | Price 30.59 | Shares 50,000
Sale 15 Jun 2023
Value US$6,886,000.00 | Price 34.43 | Shares 200,000
Proposed sale 15 Jun 2023
Value US$6,886,000.00 | Price 34.43 | Shares 200,000
Proposed sale 2 Jun 2023
Value US$62,440.25 | Price 32.95 | Shares 1,895
Planned sale 2 Jun 2023
Value US$62,440.25 | Price 32.95 | Shares 1,895
Planned sale 1 Jun 2023
Value US$1,630,070.00 | Price 32.60 | Shares 50,000
Proposed sale 1 Jun 2023
Value US$1,630,000.00 | Price 32.60 | Shares 50,000
Proposed sale 8 May 2023
Value US$1,127,008.00 | Price 32.00 | Shares 35,219
Proposed sale 8 May 2023
Value US$1,127,008.00 | Price 32.00 | Shares 35,219
Proposed sale 5 May 2023
Value US$1,106,260.20 | Price 31.41 | Shares 35,220
Planned sale 4 May 2023
Value US$9,879.00 | Price 32.93 | Shares 300
Planned sale 4 May 2023
Value US$385,286.84 | Price 31.76 | Shares 12,132
Planned sale 4 May 2023
Value US$1,178,267.72 | Price 31.36 | Shares 37,568
Proposed sale 4 May 2023
Value US$1,124,222.40 | Price 31.92 | Shares 35,220
Proposed sale 4 May 2023
Value US$1,596,000.00 | Price 31.92 | Shares 50,000
Planned sale 11 Apr 2023
Value US$1,253,130.00 | Price 25.06 | Shares 50,000
Proposed sale 11 Apr 2023
Value US$1,243,000.00 | Price 24.86 | Shares 50,000
Planned sale 3 Mar 2023
Value US$81,570.00 | Price 27.19 | Shares 3,000
Planned sale 2 Mar 2023
Value US$1,274,376.80 | Price 27.11 | Shares 47,000
Planned sale 7 Feb 2023
Value US$266,648.68 | Price 33.57 | Shares 7,942
Planned sale 7 Feb 2023
Value US$1,389,751.93 | Price 33.04 | Shares 42,058
Planned sale 5 Jan 2023
Value US$15,366.00 | Price 30.73 | Shares 500
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2024-07-03 2024-07-01 PlS Planned sale
2.2
COLES N ANTHONY
Non-Executive Director
21,103 -3.4%
98.36
US$644,444 		21,103 -3.4% 98.36 US$644,444
2024-07-01 2024-07-01 PrS Proposed sale
2.2
NEAVELLE ANTHONY COLES

Director; Officer

Executive Director
12,473
200.59
US$1,307,996 		12,473 200.59 US$1,307,996
2024-06-05 2024-06-03 PlS Planned sale
2.2
COLES N ANTHONY
Non-Executive Director
70,287 -27.1%
297.79
US$1,012,955 		70,287 -27.1% 297.79 US$1,012,955
2024-06-03 2024-06-03 PrS Proposed sale
2.2
NEAVELLE ANTHONY COLES

Director; Officer

Executive Director
50,000
40.74
US$2,037,000 		50,000 40.74 US$2,037,000
2024-05-14 2024-05-10 PlS Planned sale
2.2
COLES N ANTHONY
Non-Executive Director
50,000 -76.2%
42.10
US$2,105,125 		50,000 -76.2% 42.10 US$2,105,125
2024-05-10 2024-05-10 PrS Proposed sale
2.2
NEAVELLE ANTHONY COLES

Director

Non-Executive Director
50,000
42.30
US$2,115,000 		50,000 42.30 US$2,115,000
2024-04-03 2024-04-01 PlS Planned sale
2.2
COLES N ANTHONY
Non-Executive Director
50,000 -76.2%
42.33
US$2,116,640 		50,000 -76.2% 42.33 US$2,116,640
2024-04-01 2024-04-01 PrS Proposed sale
2.2
NEAVELLE ANTHONY COLES

Director; Officer

Executive Director
50,000
42.27
US$2,113,500 		50,000 42.27 US$2,113,500
2024-03-06 2024-03-04 PlS Planned sale
2.2
COLES N ANTHONY
Non-Executive Director
50,000 -76.2%
41.01
US$2,050,550 		50,000 -76.2% 41.01 US$2,050,550
2024-03-04 2024-03-04 PrS Proposed sale
2.2
NEAVELLE ANTHONY COLES

Director; Officer

Executive Director
50,000
41.05
US$2,052,500 		50,000 41.05 US$2,052,500
2024-03-04 2024-02-29 PlS Planned sale
2.2
COLES N ANTHONY
Non-Executive Director
50,000 -76.2%
41.16
US$2,057,890 		50,000 -76.2% 41.16 US$2,057,890
2024-02-29 2024-02-29 PrS Proposed sale
2.2
NEAVELLE ANTHONY COLES

Director; Officer

Executive Director
50,000
41.22
US$2,061,000 		50,000 41.22 US$2,061,000
2024-02-08 2024-02-07 S Sale
2.2
COLES N ANTHONY
Non-Executive Director
2,506 -13.8%
41.54
US$104,110 		2,506 -13.8% 41.54 US$104,110
2024-02-08 2024-02-07 S Sale
2.1
Renger John

Chief Scientific Officer

Officer
2,161 -25.3%
41.54
US$89,777 		2,161 -25.3% 41.54 US$89,777
2024-01-04 2024-01-02 PlS Planned sale
2.2
COLES N ANTHONY
Non-Executive Director
50,000 -94.9%
42.24
US$2,111,815 		50,000 -94.9% 42.24 US$2,111,815
2024-01-02 2024-01-02 PrS Proposed sale
2.2
NEAVELLE ANTHONY COLES

Director; Officer

Executive Director
50,000
42.40
US$2,120,000 		50,000 42.40 US$2,120,000
2023-12-28 2023-12-26 PlS Planned sale
1.5
Sanchez Ramiro

Chief Medical Officer

Officer
10,000 -40.5%
42.47
US$424,700 		10,000 -40.5% 42.47 US$424,700
2023-12-26 2023-12-26 PrS Proposed sale
1.5
RAMIRO SANCHEZ

Officer

Officer
10,000
42.47
US$424,700 		10,000 42.47 US$424,700
2023-12-27 2023-12-22 S Sale
1.4
DiPietro Kenneth

Chief Human Resources Officer

Officer
8,000 -24.5%
41.45
US$331,608 		8,000 -24.5% 41.45 US$331,608
2023-12-22 2023-12-22 PrS Proposed sale
1.4
DiPietro Kenneth

Officer

Officer
8,000
41.45
US$331,608 		8,000 41.45 US$331,608
2023-12-21 2023-12-20 S Sale
1.1
Akamine Scott

Chief Legal Officer

Officer
7,072 -49.4%
41.42
US$292,945 		7,072 -49.4% 41.42 US$292,945
2023-12-21 2023-12-20 S Sale
1.1
Bodenrader Mark

See Remarks

Officer
7,889 -30.8%
41.42
US$326,788 		7,889 -30.8% 41.42 US$326,788
2023-12-21 2023-12-20 S Sale
1.1
Tregoning Kathleen

See Remarks

Officer
6,288 -45.6%
41.42
US$260,469 		6,288 -45.6% 41.42 US$260,469
2023-12-21 2023-12-20 S Sale
1.9
ALTSCHULLER Susan

Chief Financial Officer

Officer
13,808 -44.9%
41.42
US$571,972 		13,808 -44.9% 41.42 US$571,972
2023-12-21 2023-12-20 S Sale
1.5
Sanchez Ramiro

Chief Medical Officer

Officer
10,152 -40.9%
41.42
US$420,528 		10,152 -40.9% 41.42 US$420,528
2023-12-21 2023-12-20 S Sale
1.4
DiPietro Kenneth

Chief Human Resources Officer

Officer
6,256 -20.2%
41.42
US$259,144 		6,256 -20.2% 41.42 US$259,144
2023-12-19 2023-12-15 S Sale
1.5
Sanchez Ramiro

Chief Medical Officer

Officer
7,500 -100.0%
41.39
US$310,393 		7,500 -100.0% 41.39 US$310,393
2023-12-15 2023-12-15 PrS Proposed sale
1.5
Sanchez Ramiro

Officer

Officer
7,500
41.39
US$310,392 		7,500 41.39 US$310,392
2023-12-11 2023-12-07 PlS Planned sale
1.5
Sanchez Ramiro

Chief Medical Officer

Officer
10,000 -100.0%
41.37
US$413,700 		10,000 -100.0% 41.37 US$413,700
2023-12-07 2023-12-07 PrS Proposed sale
1.1
SCOTT AKAMINE

Officer

Officer
10,000
41.37
US$413,700 		10,000 41.37 US$413,700
2023-12-07 2023-12-07 PrS Proposed sale
1.5
RAMIRO SANCHEZ

Officer

Officer
10,000
41.37
US$413,700 		10,000 41.37 US$413,700
2023-12-07 2023-12-07 PlS Planned sale
1.1
Akamine Scott

Chief Legal Officer

Officer
10,000 -95.1%
41.37
US$413,700 		10,000 -95.1% 41.37 US$413,700
2023-12-07 2023-12-05 PlS Planned sale
1.1
Akamine Scott

Chief Legal Officer

Officer
7,500 -93.6%
35.00
US$262,500 		7,500 -93.6% 35.00 US$262,500
2023-12-05 2023-12-05 PrS Proposed sale
1.1
SCOTT AKAMINE

Officer

Officer
7,500
35.00
US$262,500 		7,500 35.00 US$262,500
2023-11-16 2023-11-14 PlS Planned sale
2.2
COLES N ANTHONY
Non-Executive Director
22,824 -89.4%
25.13
US$573,455 		22,824 -89.4% 25.13 US$573,455
2023-11-09 2023-11-08 PlS Planned sale
2.2
COLES N ANTHONY
Non-Executive Director
100 -3.6%
25.16
US$2,516 		100 -3.6% 25.16 US$2,516
2023-11-09 2023-11-07 PlS Planned sale
2.2
COLES N ANTHONY
Non-Executive Director
27,076 -90.9%
25.02
US$677,555 		27,076 -90.9% 25.02 US$677,555
2023-11-07 2023-11-07 PrS Proposed sale
2.2
NEAVELLE ANTHONY COLES

Director; Officer

Executive Director
50,000
24.96
US$1,248,000 		50,000 24.96 US$1,248,000
2023-11-06 2023-11-03 PlS Planned sale
2.2
COLES N ANTHONY
Non-Executive Director
61,401 -95.8%
25.43
US$1,561,458 		61,401 -95.8% 25.43 US$1,561,458
2023-11-03 2023-11-03 PrS Proposed sale
2.2
NEAVELLE ANTHONY COLES

Director; Officer

Executive Director
50,000
24.88
US$1,244,000 		50,000 24.88 US$1,244,000
2023-11-06 2023-11-02 PlS Planned sale
2.2
COLES N ANTHONY
Non-Executive Director
38,599 -93.5%
25.19
US$972,239 		38,599 -93.5% 25.19 US$972,239
2023-11-02 2023-11-02 PrS Proposed sale
2.2
NEAVELLE ANTHONY COLES

Director; Officer

Executive Director
50,000
25.35
US$1,267,500 		50,000 25.35 US$1,267,500
2023-11-03 2023-11-01 PlS Planned sale
1.4
PATRICK DEVAL L
Non-Executive Director
30,130 -90.2%
25.00
US$753,250 		30,130 -90.2% 25.00 US$753,250
2023-11-01 2023-11-01 PrS Proposed sale
1.4
DEVAL PATRICK

Director

Non-Executive Director
30,130
25.00
US$753,250 		30,130 25.00 US$753,250
2023-10-18 2023-10-16 B Purchase
2.3
BAIN CAPITAL INVESTORS LLC
Large shareholder
5,480,052 +9.1%
22.81
US$124,999,986 		5,480,052 +9.1% 22.81 US$124,999,986
2023-10-18 2023-10-16 B Purchase
4.0
Koppel Adam
Non-Executive Director Large shareholder
5,480,052 +9.1%
22.81
US$124,999,986 		5,480,052 +9.1% 22.81 US$124,999,986
2023-10-18 2023-10-16 B Purchase
4.0
Gordon Christopher R
Non-Executive Director Large shareholder
5,480,052 +9.1%
22.81
US$124,999,986 		5,480,052 +9.1% 22.81 US$124,999,986
2023-10-17 2023-10-16 B Purchase
2.7
PERCEPTIVE ADVISORS LLC
Non-Executive Director
876,808 +8.8%
22.81
US$19,999,990 		876,808 +8.8% 22.81 US$19,999,990
2023-09-08 2023-09-07 PlS Planned sale
2.2
COLES N ANTHONY
Non-Executive Director
50,000 -94.9%
24.07
US$1,203,415 		50,000 -94.9% 24.07 US$1,203,415
2023-09-07 2023-09-07 PrS Proposed sale
2.2
NEAVELLE ANTHONY COLES

Director; Officer

Executive Director
50,000
24.26
US$1,213,000 		50,000 24.26 US$1,213,000
2023-08-07 2023-08-04 B Purchase
3.0
Burgess Paul D.

See Remarks

Officer
21,880 +inf%
22.93
US$501,794 		21,880 +inf% 22.93 US$501,794
2023-08-07 2023-08-03 B Purchase
2.7
Renaud Ronald C JR

President & CEO

Executive Director
83,857 +inf%
23.96
US$2,008,811 		83,857 +inf% 23.96 US$2,008,811
2023-07-13 2023-07-11 PlS Planned sale
2.2
COLES N ANTHONY
Non-Executive Director
50,000 -94.9%
30.03
US$1,501,340 		50,000 -94.9% 30.03 US$1,501,340
2023-07-11 2023-07-11 PrS Proposed sale
2.2
NEAVELLE ANTHONY COLES

Director; Officer

Executive Director
50,000
30.59
US$1,529,500 		50,000 30.59 US$1,529,500
2023-06-20 2023-06-15 S Sale
3.9
DEKKERS MARIJN E
Non-Executive Director
200,000 -33.2%
34.43
US$6,886,000 		200,000 -33.2% 34.43 US$6,886,000
2023-06-15 2023-06-15 PrS Proposed sale
Novalis LifeSciences Investments I, L.P.

Stockholder (1) see Remarks

Large shareholder
200,000
34.43
US$6,886,000 		200,000 34.43 US$6,886,000
2023-06-05 2023-06-02 PrS Proposed sale
1.1
Bodenrader Mark

Officer

Officer
1,895
32.95
US$62,440 		1,895 32.95 US$62,440
2023-06-05 2023-06-02 PlS Planned sale
1.1
Bodenrader Mark

See Remarks

Officer
1,895 -25.5%
32.95
US$62,440 		1,895 -25.5% 32.95 US$62,440
2023-06-05 2023-06-01 PlS Planned sale
2.2
COLES N ANTHONY

CEO and Chairperson

Executive Director
50,000 -94.9%
32.60
US$1,630,070 		50,000 -94.9% 32.60 US$1,630,070
2023-06-01 2023-06-01 PrS Proposed sale
2.2
NEAVELLE ANTHONY COLES

Director; Officer

Executive Director
50,000
32.60
US$1,630,000 		50,000 32.60 US$1,630,000
2023-05-08 2023-05-08 PrS Proposed sale
Ceesay Abraham

Officer

Officer
35,219
32.00
US$1,127,008 		35,219 32.00 US$1,127,008
2023-05-08 2023-05-08 PrS Proposed sale
Ceesay Abraham

Officer

Officer
35,219
32.00
US$1,127,008 		35,219 32.00 US$1,127,008
2023-05-05 2023-05-05 PrS Proposed sale
Ceesay Abraham

Officer

Officer
35,220
31.41
US$1,106,260 		35,220 31.41 US$1,106,260
2023-05-08 2023-05-04 PlS Planned sale
2.2
COLES N ANTHONY

CEO and Chairperson

Executive Director
300 -10.0%
32.93
US$9,879 		300 -10.0% 32.93 US$9,879
2023-05-08 2023-05-04 PlS Planned sale
2.2
COLES N ANTHONY

CEO and Chairperson

Executive Director
12,132 -80.2%
31.76
US$385,287 		12,132 -80.2% 31.76 US$385,287
2023-05-08 2023-05-04 PlS Planned sale
2.2
COLES N ANTHONY

CEO and Chairperson

Executive Director
37,568 -71.3%
31.36
US$1,178,268 		37,568 -71.3% 31.36 US$1,178,268
2023-05-04 2023-05-04 PrS Proposed sale
Ceesay Abraham

Officer

Officer
35,220
31.92
US$1,124,222 		35,220 31.92 US$1,124,222
2023-05-04 2023-05-04 PrS Proposed sale
2.2
Neavelle Anthony Coles

Director; Officer

Executive Director
50,000
31.92
US$1,596,000 		50,000 31.92 US$1,596,000
2023-04-13 2023-04-11 PlS Planned sale
2.2
COLES N ANTHONY

CEO and Chairperson

Executive Director
50,000 -94.9%
25.06
US$1,253,130 		50,000 -94.9% 25.06 US$1,253,130
2023-04-11 2023-04-11 PrS Proposed sale
2.2
Neavelle Anthony Coles

Officer

Officer
50,000
24.86
US$1,243,000 		50,000 24.86 US$1,243,000
2023-03-06 2023-03-03 PlS Planned sale
2.2
COLES N ANTHONY

CEO and Chairperson

Executive Director
3,000 -52.6%
27.19
US$81,570 		3,000 -52.6% 27.19 US$81,570
2023-03-06 2023-03-02 PlS Planned sale
2.2
COLES N ANTHONY

CEO and Chairperson

Executive Director
47,000 -94.6%
27.11
US$1,274,377 		47,000 -94.6% 27.11 US$1,274,377
2023-02-08 2023-02-07 PlS Planned sale
2.2
COLES N ANTHONY

CEO and Chairperson

Executive Director
7,942 -74.6%
33.57
US$266,649 		7,942 -74.6% 33.57 US$266,649
2023-02-08 2023-02-07 PlS Planned sale
2.2
COLES N ANTHONY

CEO and Chairperson

Executive Director
42,058 -79.8%
33.04
US$1,389,752 		42,058 -79.8% 33.04 US$1,389,752
2023-01-06 2023-01-05 PlS Planned sale
2.2
COLES N ANTHONY

CEO and Chairperson

Executive Director
500 -15.6%
30.73
US$15,366 		500 -15.6% 30.73 US$15,366
Explore more

More insider trading research around Cerevel Therapeutics Holdings Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America